SAN DIEGO, May 6, 2021 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), announced today
that it will report financial results and highlights for the
quarter ended March 31, 2021 on
Thursday, May 13, 2021, after the
U.S. financial markets close.
The Company will host a conference call and live audio webcast
on Thursday, May 13, 2021 at
5:00 pm Eastern Daylight Time to
report its first quarter 2021 financial results and provide a
corporate update. To access the call, please dial (877)
257-8599 (domestic) or (970) 315-0459 (international) and refer to
conference ID 6947037. To access the telephone replay of the
call, dial (855) 859-2056 (domestic) or (404) 537-3406
(international), passcode ID 6947037. The webcast and
telephone replay will be archived on the Company's website at
www.regulusrx.com following the call.
About Regulus
Regulus Therapeutics Inc. (Nasdaq:
RGLS) is a biopharmaceutical company focused on the discovery and
development of innovative medicines targeting
microRNAs. Regulus has leveraged its oligonucleotide drug
discovery and development expertise to develop a pipeline
complemented by a rich intellectual property estate in the microRNA
field. Regulus maintains its corporate headquarters in
San Diego, CA.
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic
and commercial potential of Regulus' business plans, technologies
and intellectual property related to microRNA therapeutics and
microRNA biomarkers being discovered and developed by
Regulus. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, and feedback from the
FDA. In addition, while Regulus expects the COVID-19 pandemic
to adversely affect its business operations and financial results,
the extent of the impact on Regulus' ability to achieve its
preclinical and clinical development objectives and the value of
and market for its common stock, will depend on future developments
that are highly uncertain and cannot be predicted with confidence
at this time, such as the ultimate duration of the pandemic, travel
restrictions, quarantines, social distancing and business closure
requirements in the U.S. and in other countries, and the
effectiveness of actions taken globally to contain and treat the
disease. These and other risks are described in
additional detail in Regulus' filings with the Securities and
Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regulus-therapeutics-announces-timing-for-first-quarter-2021-financial-results-webcast-and-conference-call-301286204.html
SOURCE Regulus Therapeutics Inc.